An observational study in Cancer Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Not yet recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Observational
The purpose of this observational study is to evaluate the effectiveness and tolerability of outpatient titration regimen with OxyContin as background for moderate and severe pain in cancer patients in adult patients with moderate to severe cancer pain. The main questions it aims to answer are
Primary Endpoints: The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 [CR (Complete remission)] or achieving a reduction of 25% when NRS score >3 [PR (Partial remission)] at 72 h.
Secondary Endpoints:
343 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
This study's planned enrollment of 378 is above the median of 140 across 70 observational studies indexed under Cancer Pain.
Browse Cancer Pain studies →Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with moderate-to-severe cancer pain treated with the outpatient OxyContin dose titration regimen，able to complete questionnaire and scale assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Outpatient OxyContin Dose Titration for Patients with Moderate-to-Severe Cancer Pain，This study is a multi-center prospective single arm real-world study with OxyContin as background titration. The study consists of 2 phases: Screening/ titration phase and maintenance phase.
The proportion of participants achieving pain relief after treatment.
Pain assessments will be performed using the BPI-SF (Brief Pain Inventory-Short Form) and NRS (Numerical Rating Scale). The proportion of participants achieving pain remission, which is defined as the rate of participants with average NRS (Numerical rating scale) score ≤3 \[CR (Complete remission)\] or achieving a reduction of 25% when NRS score \>3 \[PR (Partial remission)\] at 72 h
Time frame: From enrollment to the end of follow-up at Day 8.
Adverse events: the frequency and severity of adverse events
assessed primarily by adverse events occurring after treatment (defined as adverse events that emerge or worsen following the first dose of OxyContin), and may also be evaluated via physical examinations and vital signs.
Time frame: From enrollment to the end of follow-up at Day 8.
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers, due to privacy protection and ethical considerations. Study results may be published in the form of aggregated summary data.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mundipharma (China) Pharmaceutical Co. Ltd →